Protocol
Growth hormone (recombinant somatropin) therapy
HGH · hGH · somatropin · somatotropin · human growth hormone therapy · recombinant human growth hormone · rhGH
The human evidence for somatropin as an anti-ageing intervention is unusually well characterised, and it is not supportive. The definitive synthesis is Liu et al., a systematic review of 31 randomised controlled trials of GH in healthy elderly adults (Annals of Internal Medicine, 2007). It found small body-composition shifts (fat mass down about 2.1 kg, lean body mass up about 2.1 kg) with no demonstrated gain in strength, function, quality of life or survival, and significantly higher rates of soft tissue oedema, arthralgia, carpal tunnel syndrome, gynaecomastia, and new-onset diabetes or impaired fasting glucose. The authors concluded GH cannot be recommended as an antiaging therapy. Nothing since has overturned that: the frequently cited TRIIM trial (Fahy et al., Aging Cell, 2019) reported thymic regrowth and a roughly 1.5 to 2.5 year reduction in epigenetic age, but it enrolled only nine men, had no control arm, and combined rhGH with DHEA and metformin, so no effect can be attributed to GH alone and no clinical outcome was measured. Separately, the benefit in genuinely GH-deficient adults (pituitary disease, hypopituitarism) is real and is the basis of the registered indication, but that population is not the ageing population these clinics are marketing to. There is also a documented harm signal in the other direction: lower GH/IGF-1 signalling is associated with longer life in multiple model organisms and in human GH-receptor-deficiency cohorts, so the mechanistic rationale for supplementing GH to extend healthspan is contested rather than merely unproven. Chronic supraphysiological GH causes acromegaly, insulin resistance, and cardiovascular disease. Even the Singapore clinic pages advertising the treatment state plainly that HGH is not the anti-ageing miracle it is claimed to be.
At a glance
- Evidence
- Clinical
- Singapore (HSA)
- Somatropin is registered with HSA as a prescription-only therapeutic product in Singapore (registered brands include Norditropin, Saizen and SciTropin A) and is listed on the National Drug Formulary. The registered indications are growth hormone deficiency and conditions causing short stature, plus replacement therapy in adults with GH deficiency associated with hypothalamic or pituitary disease. Any use for age-related decline or general 'anti-ageing' in an adult without diagnosed deficiency is off-label. It is available only on a doctor's prescription; unregistered HGH products sold outside that channel are illegal under HSA regulation. Note: I did not open a specific HSA product register entry, so the brand-level registration detail rests on the National Drug Formulary and HealthHub listings rather than a direct register lookup.
- Australia (TGA)
- Somatropin is TGA-registered in Australia as a Schedule 4 Prescription Only Medicine. Genotropin, for example, is registered for short stature due to decreased or failed pituitary growth hormone secretion, severe adult growth hormone deficiency, Turner syndrome, Prader-Willi syndrome and growth disturbance in chronic renal insufficiency. Long-acting analogues have since been registered for paediatric GHD (Skytrofa/lonapegsomatropin was TGA-approved in 2025). PBS subsidy is restricted to childhood-onset or late-onset severe growth hormone deficiency and requires treatment by an endocrinologist. There is no TGA-approved indication for anti-ageing, healthspan, or performance and image enhancement; Australian authorities state that GH and GH-raising peptides are permitted only for legitimate medical purposes on prescription and are not approved for performance or image enhancement. The TGA has issued alerts about unapproved imported somatropin and peptide products.
- Offered at
- No clinic on file
Singapore
Health Sciences Authority
- HSA status
- Somatropin is registered with HSA as a prescription-only therapeutic product in Singapore (registered brands include Norditropin, Saizen and SciTropin A) and is listed on the National Drug Formulary. The registered indications are growth hormone deficiency and conditions causing short stature, plus replacement therapy in adults with GH deficiency associated with hypothalamic or pituitary disease. Any use for age-related decline or general 'anti-ageing' in an adult without diagnosed deficiency is off-label. It is available only on a doctor's prescription; unregistered HGH products sold outside that channel are illegal under HSA regulation. Note: I did not open a specific HSA product register entry, so the brand-level registration detail rests on the National Drug Formulary and HealthHub listings rather than a direct register lookup.
- In our SG set
- Tracked in Singapore
- SG clinics
- None on file
Australia
Therapeutic Goods Administration
- TGA status
- Somatropin is TGA-registered in Australia as a Schedule 4 Prescription Only Medicine. Genotropin, for example, is registered for short stature due to decreased or failed pituitary growth hormone secretion, severe adult growth hormone deficiency, Turner syndrome, Prader-Willi syndrome and growth disturbance in chronic renal insufficiency. Long-acting analogues have since been registered for paediatric GHD (Skytrofa/lonapegsomatropin was TGA-approved in 2025). PBS subsidy is restricted to childhood-onset or late-onset severe growth hormone deficiency and requires treatment by an endocrinologist. There is no TGA-approved indication for anti-ageing, healthspan, or performance and image enhancement; Australian authorities state that GH and GH-raising peptides are permitted only for legitimate medical purposes on prescription and are not approved for performance or image enhancement. The TGA has issued alerts about unapproved imported somatropin and peptide products.
- In our AU set
- Tracked in Australia
- AU clinics
- None on file
Evidence is not approvalAn evidence grade describes how strong the science is. A regulatory status describes whether a body has approved the intervention for an indication. They are different questions, answered separately above.
What it is
Plain-language explainer
Somatropin is recombinant human growth hormone, a biosynthetic copy of the pituitary hormone, given as a subcutaneous injection (typically daily, with newer long-acting analogues weekly). It is a registered prescription medicine in both Singapore and Australia for diagnosed growth hormone deficiency and a small number of named paediatric growth disorders. In the longevity market it is promoted off-label to older adults on the claim that restoring youthful GH and IGF-1 levels increases lean mass, reduces fat mass, improves bone density, energy and recovery, and slows biological ageing.
Categories
Protocol
Keep reading
Related coverage from the newsroom.
Sources
What this profile is built on
- Systematic review: the safety and efficacy of growth hormone in the healthy elderly (Liu et al., Ann Intern Med 2007;146:104-15) · PubMed / Annals of Internal Medicine
- No proof that growth hormone therapy makes you live longer, Stanford study finds · Stanford Medicine
- Reversal of epigenetic aging and immunosenescent trends in humans (TRIIM trial, Fahy et al., 2019) · Aging Cell / Wiley
- Genotropin (somatropin): Australian indications, Schedule 4 Prescription Only Medicine · healthdirect Australia
- Growth hormone deficiency, childhood onset or late onset: PBS somatropin criteria · Services Australia
- About the shortage of somatropin products · Therapeutic Goods Administration (TGA)
- TGA approves Skytrofa (lonapegsomatropin) for paediatric growth hormone deficiency in Australia · Specialised Therapeutics
- Peptides in Australia: what you need to know (GH permitted only for legitimate medical purposes, not for performance or image enhancement) · Healthy Male (Australian Government funded)
- Growth hormone injections (somatropin): Singapore patient information · HealthHub, Singapore Ministry of Health
- Somatropin [Norditropin], Singapore National Drug Formulary listing · National Drug Formulary, Singapore
- Illegal health products found in Singapore · Health Sciences Authority (HSA)
- Human growth hormone treatment, HGH clinic Singapore (DTAP) - adult HGH by daily subcutaneous injection, prescription only, states HGH is not an anti-ageing miracle · DTAP Clinic / mens-health.sg
- Human growth hormone (HGH) service page · TAF Clinic Singapore
- Human growth hormone (HGH): Does it slow aging? · Mayo Clinic
Every entity profile on variis is sourced. Not medical advice.